Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04676633 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, PK, Anti-Tumor Activity of STP705 in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy
A Phase 1 study, sponsored by Sirnaomics.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT04676633 is a Phase 1 study that has completed, run by Sirnaomics. The registered enrollment target is 5 participants.
The verdict
NCT04676633, a Phase 1 study, has completed, sponsored by Sirnaomics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is an open label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of STP705 administered intratumorally in cholangiocarcinoma, hepatocellular carcinoma or liver metastasis in subjects with advanced/metastatic or surgically unresectable solid tumors who are refractory to standard therapy. Goals: 1. To determine the MTD or RP2D of STP705 when administered intratumorally into cholangiocarcinoma, hepatocellular carcinoma, or liver metastasis. 2. To establish the dose of STP705 recommended for future phase 2 studies when administered intratumorally.
Interventions
- DRUG STP705
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2021-03-01 |
| Est. Completion | 2023-01-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04676633
The ClinicalTrials.gov registry entry for NCT04676633 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sirnaomics, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which STP705 is the first listed.
NCT04676633 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04676633 about?
NCT04676633 is a clinical study titled "Safety, Tolerability, PK, Anti-Tumor Activity of STP705 in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy". This is an open label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of STP705 administered intratumorally in cholangiocarcinoma, hepatocellular carcinoma or liver metastasis in subjects with advanced/metastatic or surgically...
What is the current status of trial NCT04676633?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2021-03-01. Estimated completion is 2023-01-13.
What interventions are being tested in trial NCT04676633?
The interventions under investigation include: STP705 (DRUG).
Who is sponsoring clinical trial NCT04676633?
This trial is sponsored by Sirnaomics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.